Literature DB >> 16761621

Mutational analysis of K-ras and Ras protein expression in larynx squamous cell carcinoma.

L M Ruíz-Godoy R1, C M Garcia-Cuellar, N E Herrera González, B L Suchil, E Pérez-Cárdenas, Y Sácnchez-Pérez, M L Suárez-Roa, A Meneses.   

Abstract

The ras gene family (H, K and N-ras) encodes the Ras protein, a GTPase-activating protein that regulates several signal transduction pathways including cellular proliferation and differentiation. Mutations in codons 12, 13 and 61 of the ras genes constitute one of the most frequent alterations in human cancer. In the Western Hemisphere, a low frequency of mutations in these genes has been observed in head and neck carcinomas; a higher frequency has been found in countries such as India and Taiwan. Increased protein expression is a relatively frequent event in larynx carcinomas. This study was aimed to evaluate the participation of the k-ras gene and Ras expression in 20 Mexican patients with larynx squamous carcinoma, 2 with dysplasia and 4 with normal mucosa. Samples (of 26 patients) were embedded in paraffin and immunohistochemical analysis was performed for the Ras protein, as well as amplification of the k-ras gene exon 1 (108 bp) by laser capture microdissection. Then, DNA extraction, PCR and sequencing were performed looking for possible mutation in codons 12 and 13. All patients with larynx carcinoma were men, median age 62 years. Eighty-five percent of the patients had risk factors such as smoking and/or alcohol consumption, 25% were in clinical stages I and II, and 75% in stages III and IV; 45% of the patients presented tumor recurrence or persistence. In this study, no mutations were found in codons 12 or 13 of the k-ras gene; however, protein expression was observed in 95% of the samples and a higher expression of the protein was associated with tumor recurrence or persistence, although this was not statistically significant. Unexpectedly, well-differentiated carcinomas and dysplasias presented an increase in protein expression. These results suggest that ras may be involved in early stages of larynx carcinogenesis and may be activated by other mechanisms different from mutations, such as epigenetic events.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16761621

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  8 in total

Review 1.  Molecular therapy in head and neck oncology.

Authors:  Jacques Bernier; Søren M Bentzen; Jan B Vermorken
Journal:  Nat Rev Clin Oncol       Date:  2009-05       Impact factor: 66.675

Review 2.  Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

Authors:  Carolien Boeckx; Marc Baay; An Wouters; Pol Specenier; Jan B Vermorken; Marc Peeters; Filip Lardon
Journal:  Oncologist       Date:  2013-07-02

Review 3.  Emerging drugs to treat squamous cell carcinomas of the head and neck.

Authors:  Christopher Fung; Jennifer R Grandis
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

4.  Worldwide Prevalence and Clinical Characteristics of RAS Mutations in Head and Neck Cancer: A Systematic Review and Meta-Analysis.

Authors:  Ofra Novoplansky; Sankar Jagadeeshan; Ohad Regev; Idan Menashe; Moshe Elkabets
Journal:  Front Oncol       Date:  2022-05-06       Impact factor: 5.738

5.  Impact of K-Ras Over-expression in Laryngeal Squamous Cell Carcinoma.

Authors:  Vasileios Papanikolaou; Aristeidis Chrysovergis; Stylianos Mastronikolis; Evangelos Tsiambas; Vasileios Ragos; Dimitrios Peschos; Despoina Spyropoulou; Pavlos Pantos; Athanasios Niotis; Nicholas Mastronikolis; Efthymios Kyrodimos
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

6.  A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.

Authors:  Roland H Stauber; Shirley K Knauer; Negusse Habtemichael; Carolin Bier; Britta Unruhe; Simona Weisheit; Stephanie Spange; Frank Nonnenmacher; Verena Fetz; Torsten Ginter; Sigrid Reichardt; Claus Liebmann; Günter Schneider; Oliver H Krämer
Journal:  Oncotarget       Date:  2012-01

7.  Prevalence of K-RAS Codons 12 and 13 Mutations in Locally Advanced Head and Neck Squamous Cell Carcinoma and Impact on Clinical Outcomes.

Authors:  Eric Bissada; Olivier Abboud; Zahi Abou Chacra; Louis Guertin; Xiaoduan Weng; Phuc Félix Nguyen-Tan; Jean-Claude Tabet; Eve Thibaudeau; Louise Lambert; Marie-Lise Audet; Bernard Fortin; Denis Soulières
Journal:  Int J Otolaryngol       Date:  2013-04-30

8.  KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia.

Authors:  Jing-Dong Zhou; Dong-Ming Yao; Xi-Xi Li; Ting-Juan Zhang; Wei Zhang; Ji-Chun Ma; Hong Guo; Zhao-Qun Deng; Jiang Lin; Jun Qian
Journal:  Oncotarget       Date:  2017-08-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.